US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020

JAMA Intern Med. 2020 Oct 1;180(10):1384-1386. doi: 10.1001/jamainternmed.2020.2594.

Abstract

This study examines how the prescription of hydroxychloroquine and chloroquine to outpatients has changed in the United States during the coronavirus disease 2019 pandemic.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Infective Agents / pharmacology
  • Azithromycin / pharmacology*
  • Betacoronavirus
  • COVID-19
  • Chloroquine / pharmacology*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / prevention & control*
  • Databases, Pharmaceutical / statistics & numerical data
  • Drug Prescriptions / statistics & numerical data
  • Humans
  • Hydroxychloroquine / pharmacology*
  • Outpatients / statistics & numerical data
  • Pandemics / prevention & control*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / prevention & control*
  • Practice Patterns, Physicians' / trends*
  • Pre-Exposure Prophylaxis / methods*
  • Prescription Drug Monitoring Programs / statistics & numerical data
  • SARS-CoV-2
  • United States / epidemiology

Substances

  • Anti-Infective Agents
  • Hydroxychloroquine
  • Azithromycin
  • Chloroquine